News | Radiation Therapy | November 11, 2016

British Device Maker Pays $36 Million to U.S. Government for Off-Label Product Promotion

False Claims Act lawsuit revealed BTG subsidiary Biocompatibles fraudulently marketed its LC Bead device for uses that had been denied approval by the FDA

November 11, 2016 — British medical device maker BTG PLC and its subsidiary, Biocompatibles Inc., have agreed to pay $36 million to the U.S. government to resolve federal and state False Claims Act (FCA) allegations resulting from the off-label promotion of LC Bead, a medical device approved for use only for embolization of hypervascular tumors. $25 million of the settlement is to resolve the civil qui tam action, which alleged fraud, and $11 million of the settlement is a criminal fine against Biocompatibles.

The whistleblower, Ryan Bliss, is represented by Jeffrey A. Newman Esq., of Jeffrey Newman Law, and co-counsel Paul Lawrence II of Waters & Kraus of Dallas. In the complaint, Bliss, who oversaw marketing of Biocompatibles’ medical products in North America, revealed detailed information alleging that Biocompatibles lied to the U.S. Food and Drug Administration (FDA) about a drug delivery device called LC Bead and sold it for millions of dollars in the United States without clearance.

The suit alleged that Biocompatibles violated marketing regulations in its promotion activities to U.S. doctors, pushing LC Bead as a chemotherapy drug-delivery device that physicians could use for treatment of patients with various forms of cancer — a use the FDA had never approved. LC Bead was only cleared by the FDA for so-called “bland” embolization of blood vessels (i.e. blocking of blood supply) for the treatment of hypervascular tumors. The unapproved use of LC Bead as a drug-delivery device (wherein the beads are loaded with a chemotherapy drug) caused healthcare providers across the country to submit false claims for payment to Medicare, Medicaid and other federal healthcare programs, the government alleged.

In 2009, Biocompatibles, which has its headquarters in Britain, filed with the FDA for Premarket Approval (PMA) of LC Bead to deliver chemotherapy drugs in humans. The FDA denied approval, stating there was not enough evidence demonstrating sufficient survival benefit to patients. Despite this, the company continued to sell the LC Bead in the United States for use as a drug delivery device and continues to do so. While Biocompatibles pleaded guilty to criminal charges that the company violated a law that prohibits the introduction of misbranded medical devices into interstate commerce, none of the management was prosecuted for any criminal wrongdoing.

“What’s remarkable about this case is that Biocompatibles had obtained clearance from the FDA for one use, when LC Bead was specifically designed and exclusively marketed to U.S. doctors for a completely different use that the FDA had refused to approve. The company went on to instruct providers to submit claims using the code established for approved procedures knowing that insurers would have denied coverage otherwise,” said attorney Newman. 

LC Bead continues to be sold as drug-eluting beads throughout the United States, and the same product is sold outside the United States but is marketed under the name DC Bead. The federal government and various states will receive a portion of the funds to settle allegations of fraudulent billing to Medicaid programs.

Bliss was awarded a portion of the funds collected by the government in this case pursuant to The False Claims Act, which allows private citizens to file actions on behalf of the government revealing fraudulent billing of government agencies.

For more information: www.jeffreynewmanlaw.com

Related Content

Videos | Image Guided Radiation Therapy (IGRT) | October 15, 2018
Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute, describes the benefits the departm
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
ASTRO 2018 Radiation Therapy Clinical Trials
Feature | ASTRO | October 08, 2018
October 8, 2018 — The American Society for Radiation Oncology (ASTRO) announced the 10 top-rated clinical studies tha
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Videos | Treatment Planning | October 05, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
Videos | Image Guided Radiation Therapy (IGRT) | October 04, 2018
Carrie Glide-Hurst, Ph.D., and Benjamin Movsas, M.D., discuss Henry Ford Hospital's involvement in a national clinica
Miami Cancer Institute

The Miami Cancer Institute team.

Sponsored Content | Case Study | Radiation Therapy | October 04, 2018
Miami Cancer Institute, a part of Baptist Health South Florida, is a state-of-the-art center that serves as the primary...